ENANTA PHARMACEUTICALS, INC Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
ENANTA PHARMACEUTICALS, INC (ENTA) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $13.00 thousand for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $13.00K, a 18.18% increase from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $11.00K, a 92.95% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $156.00K, a 57.49% decline from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $367.00K, a 173.88% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 9 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|---|
| 2025-09-30 | $13.00K 10-K · filed 2025-11-19 | |
| 2024-09-30 | $11.00K 10-K · filed 2025-11-19 | |
| 2023-09-30 | $156.00K 10-K · filed 2024-11-27 | |
| 2022-09-30 | $367.00K 10-K · filed 2023-11-22 | |
| 2021-09-30 | $134.00K 10-K · filed 2022-11-23 | |
| 2020-09-30 | $719.00K 10-K · filed 2021-11-24 | |
| 2019-09-30 | $87.00K 10-K · filed 2020-11-25 | $87.00K 10-K · filed 2019-11-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |